Cost-effectiveness of Intravitreal Ranibizumab With Verteporfin Photodynamic Therapy Compared With Ranibizumab Monotherapy for Patients With Polypoidal Choroidal Vasculopathy

IMPORTANCE: The EVEREST II trial showed that for patients with polypoidal choroidal vasculopathy (PCV), intravitreal ranibizumab in combination with verteporfin photodynamic therapy improves visual acuity relative to ranibizumab monotherapy. However, whether combination therapy is incrementally cost...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA Ophthalmol
Main Authors: Doble, Brett, Finkelstein, Eric Andrew, Tian, Yubing, Saxena, Nakul, Patil, Shiva, Wong, Tien Yin, Cheung, Chui Ming Gemmy
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2020
Assuntos:
Original Investigation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6990685/
https://ncbi.nlm.nih.gov/pubmed/31917395
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaophthalmol.2019.5628
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares